1. Home
  2. XMTR vs RYTM Comparison

XMTR vs RYTM Comparison

Compare XMTR & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xometry Inc.

XMTR

Xometry Inc.

SELL

Current Price

$109.49

Market Cap

5.8B

Sector

Technology

ML Signal

SELL

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$104.05

Market Cap

6.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XMTR
RYTM
Founded
2013
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
6.3B
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
XMTR
RYTM
Price
$109.49
$104.05
Analyst Decision
Buy
Strong Buy
Analyst Count
12
19
Target Price
$116.18
★ $140.29
AVG Volume (30 Days)
787.0K
★ 1.1M
Earning Date
11-03-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
26.95
★ 28.34
EPS
★ N/A
N/A
Revenue
★ $686,631,000.00
N/A
Revenue This Year
$37.27
$73.80
Revenue Next Year
$20.15
$73.86
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 25.87
N/A
52 Week Low
$35.86
$74.50
52 Week High
$117.50
$122.20

Technical Indicators

Market Signals
Indicator
XMTR
RYTM
Relative Strength Index (RSI) 63.81 70.69
Support Level $82.69 $98.83
Resistance Level N/A $117.84
Average True Range (ATR) 8.23 5.13
MACD 1.73 1.91
Stochastic Oscillator 87.43 94.41

Price Performance

Historical Comparison
XMTR
RYTM

About XMTR Xometry Inc.

Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: